metabolite comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-13. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
== In vitro self-assembly == Measuring approximately 7 nm in diameter, microfilaments are the thinnest fibers of the cytoskeleton. They are polymers of actin subunits (globular actin, or G-actin), which as part of the fiber are referred to as filamentous actin, or F-actin. Each microfilament is made up of two helical, interlaced strands of subunits. Much like microtubules, actin filaments are polarized. Electron micrographs have provided evidence of their fast-growing barbed-ends and their slow-growing pointed-end. This polarity has been determined by the pattern created by the binding of myosin S1 fragments: they themselves are subunits of the larger myosin II protein complex. The pointed end is commonly referred to as the minus (−) end and the barbed end is referred to as the plus (+) end. In vitro actin polymerization, starts with the self-association of three G-actin monomers to form a trimer. ATP-bound actin then itself binds the barbed end, and the ATP is subsequently hydrolyzed. ATP hydrolysis occurs with a half time of about 2 seconds, while the half time for the dissociation of the inorganic phosphate is about 6 minutes. This autocatalyzed event reduces the binding strength between neighboring subunits, and thus generally destabilizes the filament. In vivo actin polymerization is catalyzed by a class of filament end-tracking molecular motors known as actoclampins. Evidence suggests that the rate of ATP hydrolysis and the rate of monomer incorporation are strongly coupled.
These medications may suppress appetite, make food taste different, or affect how nutrients are absorbed, making it even less likely seniors will get the required nutrients. 8% of seniors suffer from hyponatremia, although it is unclear how much of that is due to "tea and toast" diets. The prevalence of hyponatremia in the elderly population may be even higher in health care settings. Hyponatremia is believed to arise as a result of a diet poor in salt and protein with large water intake in combination with a low glomerular filtration rate (GFR). The low GFR causes a lowered rate of osmole excretion, and an increase in the amount of water reabsorbed; thus, hyponatremia occurs when the amount of water intake exceeds the renal water excretion capacity. Medications, such as thiazides and antidepressants, may exacerbate symptoms of hyponatremia.
=== SARM1 === SARM1 is a Toll-like receptor protein and also functions as a intracellular NADase. Under normal circumstances NADase activity are inhibited in the presence of NAD+, where NAD+ binds to armadillo/heat motifs (ARMs), which inhibits the dimerization of the toll-like receptor domain that activates the NADase activity. If there are damages to the binding site of NAD+ or disruption that prevents the interaction between ARMs and the toll-like receptor domain, NADase activity will be turned on at a constitutive level. As a result SARM1 will have higher consumption of NAD+ and produce NADase products (ADP-ribose and nicotinamide) rather than the production of cADPR from ADP-ribosyl cyclase.
In October 1938, Joachim von Ribbentrop first proposed German-Polish territorial adjustments and Poland's participation in the Anti-Comintern Pact against the Soviet Union. The status of the Free City of Danzig was one of the key bones of contention. Approached by Ribbentrop again in March 1939, the Polish government expressed willingness to address issues causing German concern, but effectively rejected Germany's stated demands and thus refused to allow Poland to be turned by Adolf Hitler into a German puppet state. Hitler, incensed by the British and French declarations of support for Poland, abrogated the German–Polish declaration of non-aggression in late April 1939. To protect itself from an increasingly aggressive Nazi Germany, already responsible for the annexations of Austria (in the Anschluss of 1938), Czechoslovakia (in 1939) and a part of Lithuania after the 1939 German ultimatum to Lithuania, Poland entered into a military alliance with Britain and France (the 1939 Anglo-Polish military alliance and the Franco-Polish alliance (1921), as updated in 1939). However, the two Western powers were defense-oriented and not in a strong position, either geographically or in terms of resources, to assist Poland. Attempts were therefore made by them to induce Soviet-Polish cooperation, which they viewed as the only militarily viable arrangement. Diplomatic manoeuvers continued in the spring and summer of 1939, but in their final attempts, the Franco-British talks with the Soviets in Moscow on forming an anti-Nazi defensive military alliance failed.
Sources: en.wikipedia.org
== Economics == Since 2000, the therapeutic market for monoclonal antibodies has grown exponentially. In 2006, the "big 5" therapeutic antibodies on the market were bevacizumab, trastuzumab (both oncology), adalimumab, infliximab (both autoimmune and inflammatory disorders, 'AIID') and rituximab (oncology and AIID) accounted for 80% of revenues in 2006. In 2007, eight of the 20 best-selling biotechnology drugs in the U.S. are therapeutic monoclonal antibodies. This rapid growth in demand for monoclonal antibody production has been well accommodated by the industrialization of mAb manufacturing.
A few dozen nitriles are used as fragrance ingredients in cosmetics. These include cinnamic acid nitrile, dodecanitrile, benzonitrile, and geranyl nitrile. Some nitriles possess fragrances similar to those of the corresponding aldehydes but are considerably more stable, making them suitable substitutes. For example, geranyl nitrile provides a citrus note and, unlike the structurally analogous citral, is resistant to oxidation. Various nitriles are employed as pesticides. Cyano groups are present in certain pyrethroids. Pyrethroids are carboxylic acid esters; by using 3-phenoxymandelonitrile as the alcohol component, as in deltamethrin and cypermethrin, a class of particularly potent derivatives has been developed. Azoxystrobin became the world's best-selling agricultural fungicide in 1999, only a few years after its introduction, with sales exceeding 400 million US dollars, and it has retained its market significance for more than 15 years, remaining the leading fungicide in 2016. Azoxystrobin was developed on the basis of the naturally occurring strobilurin. Key structural modifications relative to the parent compound include replacement of double bonds with aromatic rings and introduction of a cyano group onto the pre-existing ring system. A widely used nitrile-containing insecticide is fipronil. cyanoacrylates are used as adhesives because, as single-component formulations, they cure rapidly under ambient conditions and can bond a wide range of materials.
YAN is a measurement of the primary organic (free amino acids) and inorganic (ammonia and ammonium) sources of nitrogen that can be assimilated by S. cerevisiae. There are several nitrogenous compounds found in must and wine including peptides, larger proteins, amides, biogenic amines, pyridines, purines and nucleic acids but these cannot be directly used by yeast for metabolism. Taken together, the total nitrogen content of grape must can range from 60 to 2400 mg of nitrogen per liter, however not all of this nitrogen will be assimilable. The lack of protease enzymes, which break down larger peptides into smaller components, that can work outside the cell, limits the size of the molecules that yeast can use as a source for nitrogen. The amount of YAN that winemakers will see in their grape musts depends on a number of components including grape variety, rootstock, vineyard soils and viticultural practices (such as the use of fertilizers and canopy management) as well as the climate conditions of particular vintages. Infections by mold, such as Botrytis cinerea (known as noble rot when it is desired) can reduce the amino acid content of grape must by as much as 61%. Some regions are noted for having low YAN such as Washington State which during a typical vintage will have 90% of tested must below 400 mg N/L and nearly a quarter be below 150 mg N/L. In the vineyard, nitrogen is taken up by the grapevine as nitrate (NO3−), ammonium or urea which gets reduced into ammonia.
In December 1978, Gaddafi stepped down as Secretary-General of the GPC, announcing his new focus on revolutionary rather than government activities; this was part of his new emphasis on separating the apparatus of the revolution from government. Although no longer in a formal government post, he adopted the title of "Leader of the Revolution" and continued as commander-in-chief of the armed forces. Historian Dirk Vandewalle stated that despite the Jamahariya's claims to being a direct democracy, Libya remained "an exclusionary political system whose decision-making process" was "restricted to a small cadre of advisers and confidantes" surrounding Gaddafi. Libya started constructing a welfare state. In March 1978, the government issued guidelines for housing redistribution, attempting to ensure every adult owned their own home. Most families were banned from owning more than one house, while former rental properties were expropriated by the state and sold to the tenants at a heavily subsidized price. In September, Gaddafi called for the People's Committees to eliminate the "bureaucracy of the public sector" and the "dictatorship of the private sector"; the People's Committees took control of several hundred companies, converting them into worker cooperatives run by elected representatives. In March 1979, the GPC announced the separation of government and revolution, the latter being represented by new Revolutionary Committees, who operated with the People's Committees in schools, universities, unions, the police force, and the military.
Similarly, modifications to the tRNA-linked bases that differ from the host system may reduce the translation of proteins quantitatively and qualitatively. For example, translating a foreign gene in another host system that did not contain the required tRNA resulted in early termination at the codon where the tRNA was missing. Collectively, with heterologous expression, when the host translation systems are different from the native system that the genes are being introduced from, coding errors, frameshifts, or premature or improper sequence termination are frequent. Consequently, this leads to a lower yield of functional proteins or unintended overexpression of the protein. These errors are especially prominent with the significant and unnatural increase in demand for host system biological machinery. Often, this causes the reallocation of cellular resources from normal processes to the production of the heterologous protein. Specifically, this strains tRNA and amino acid supply, quality control systems and secretion systems, as well as NADPH required for anabolic processes. Moreover, unnatural heterologous protein buildup also leads to adverse host effects. Overall the implications are not only evident in low product yields but also host stress responses and decreased host viability. There are many areas of active research addressing these limitations of utilizing heterologous expression, especially in a commercial setting.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.